EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen Access

Skin-Specific Outcomes of Brepocitinib in Patients With Dermatomyositis

Aaron R Mangold, Anna Haemel, Neda Shahriari, Benjamin Chong, Anthony P Fernandez, David Fiorentino, David Pearson, Jason Sluzevich, Oluwakemi Onajin, Pranita V Rambhatla, Mehdi Rashighi, Charlotte Hurabielle und 23 weitere

JAMA Dermatology · 01.10.2026 · 162 (10) · 1026

DOI: 10.1001/jamadermatol.2026.3199 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JAMA Dermatology, erschienen am 01.10.2026. Verfasst von Aaron R Mangold und 34 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Mayo Clinic, Scottsdale, Arizona. Hauptthemen laut MEDLINE: Dermatomyositis, Tyrosine Kinase Inhibitors, Janus Kinase Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Brepocitinib, a first-in-class oral, selective TYK2 and JAK1 inhibitor, demonstrated broad efficacy in a phase 3 randomized clinical trial in dermatomyositis.

Objective

To evaluate the effects of brepocitinib on cutaneous disease activity, itch, skin-related quality of life (QOL), and achievement of remission-level end points in adults with dermatomyositis over 52 weeks of treatment. Design, Setting, and Participants This prespecified secondary analysis of the 52-week, phase 3, double-blind, placebo-controlled, randomized VALOR clinical trial, conducted from October 2022 to July 2025 at 90 sites in 20 countries, included adults with dermatomyositis and active skin and muscle disease.

Intervention

Once-daily brepocitinib, 30 mg; brepocitinib, 15 mg; or placebo. Main Outcomes and Measures Key secondary outcomes in VALOR included change in the Cutaneous Dermatomyositis Disease Area and Severity Index–Activity (CDASI-A) score and achievement of clinically meaningful CDASI-A response (≥40% relative and ≥4-point absolute improvement). Exploratory outcomes included itch (Peak Pruritus Numeric Rating Scale [PP-NRS]); skin-related QOL (Skindex-16); achievement of Cutaneous Dermatomyositis Activity–Investigator’s Global Assessment (CDA-IGA) score of 0 (clear) or 1 (almost clear) with at least a 2-point improvement; and functional skin remission (CDASI-A ≤5). Between-group differences were analyzed using ANCOVA or Cochran-Mantel-Haenszel methods.

Results

The VALOR trial enrolled 241 participants (mean [SD] age, 50.6 [13.3] years; 187 [77.6%] female; 54 [22.4%] male). Beginning at week 4, brepocitinib, 30 mg, demonstrated superiority over placebo in mean (SD) change from baseline in CDASI-A score (−6.4 [5.8] vs −3.5 [6.0], respectively; difference, −3.0; 95% CI, −4.6 to −1.4; P < .001) and resulted in greater achievement of clinically meaningful CDASI-A response (27 participants [33.3%] vs 14 participants [17.7%], respectively; difference, 15.1 percentage points [pp]; 95% CI, 1.7-28.6 pp), itch remission (PP-NRS ≤1: 31 participants [38.3%] vs 15 participants [19.0%], respectively; difference, 18.9 pp; 95% CI, 5.0-32.9 pp) and improvement in skin-related QOL (Skindex-16 score: −12.9 [21.6] vs −0.9 [22.4], respectively; difference, −11.9; 95% CI, −17.9 to −6.0). Benefits on these measures were observed at all time points from week 4 through week 52. Among the 155 participants (64.3%) with moderate to severe skin disease at baseline, brepocitinib, 30 mg, was also associated with higher rates of achievement of a CDA-IGA score of clear or almost clear compared with placebo (21 participants [45.7%] vs 12 participants [21.8%], respectively; difference, 21.1 pp at week 52; 95% CI, 2.5-39.7 pp) and functional skin remission (20 participants [43.5%] vs 11 participants [20.8%], respectively; difference at week 52, 26.6 pp; 95% CI, 7.6-45.5 pp). Brepocitinib exhibited a safety profile consistent with approved JAK and TYK2 inhibitors. Conclusions and Relevance In this secondary analysis of a randomized clinical trial in dermatomyositis, once-daily brepocitinib, 30 mg, resulted in rapid, durable, and remission-level control of skin disease with an acceptable safety profile. Trial Registration ClinicalTrials.gov Identifier: NCT05437263

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DermatomyositisTyrosine Kinase InhibitorsJanus Kinase InhibitorsAdultFemaleHumansMaleMiddle AgedDouble-Blind MethodPruritusQuality of LifeRemission InductionSeverity of Illness IndexTreatment OutcomeJanus Kinase 1TYK2 Kinase

Substanzen

JAK1 protein, humanJanus Kinase 1TYK2 protein, humanTYK2 KinaseTyrosine Kinase InhibitorsJanus Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Dermatology, Mayo Clinic, Scottsdale, Arizona.
  • Department of Dermatology, University of California, San Francisco.
  • Mass General Brigham Department of Dermatology, Harvard Medical School, Boston, Massachusetts.
  • Department of Dermatology, UT Southwestern, Dallas, Texas.
  • Department of Dermatology and Pathology, Cleveland Clinic, Cleveland, Ohio.
  • Department of Dermatology, Stanford University School of Medicine, Stanford, California.

Zitieren

APA

Mangold, A. R., Haemel, A., Shahriari, N., Chong, B., Fernandez, A. P., Fiorentino, D., Pearson, D., Sluzevich, J., Onajin, O., Rambhatla, P. V., Rashighi, M., Hurabielle, C., Fivenson, D., Boh, E., Paravar, T., Crew, A., Flowers, R. H., Taylor, D., Subhadarshani, S., …, & Werth, V. P. (2026). Skin-Specific Outcomes of Brepocitinib in Patients With Dermatomyositis. JAMA Dermatology, 162(10), 1026. https://doi.org/10.1001/jamadermatol.2026.3199

Vancouver

Mangold AR, Haemel A, Shahriari N, Chong B, Fernandez AP, Fiorentino D, et al. Skin-Specific Outcomes of Brepocitinib in Patients With Dermatomyositis. JAMA Dermatology. 2026;162(10):1026. doi:10.1001/jamadermatol.2026.3199

BibTeX
@article{Mangold2026,
  author = {Mangold, Aaron R and Haemel, Anna and Shahriari, Neda and Chong, Benjamin and Fernandez, Anthony P and Fiorentino, David and Pearson, David and Sluzevich, Jason and Onajin, Oluwakemi and Rambhatla, Pranita V and Rashighi, Mehdi and Hurabielle, Charlotte and Fivenson, David and Boh, Erin and Paravar, Taraneh and Crew, Ashley and Flowers, R Hal and Taylor, Dustin and Subhadarshani, Sweta and Culton, Donna and Schadt, Courtney and Callen, Jeffrey and Lam, Christina and Graham, Lauren and Hashemi, Kimberly and Castillo, Rochelle and Maderal, Andrea and Elman, Scott and Shaw, Katharina S and Cascino, Matthew D and LaChance, Avery and Min, Michelle S and Femia, Alisa and Vleugels, Ruth Ann and Werth, Victoria P},
  title = {Skin-Specific Outcomes of Brepocitinib in Patients With Dermatomyositis},
  journal = {JAMA Dermatology},
  year = {2026},
  volume = {162},
  number = {10},
  pages = {1026},
  doi = {10.1001/jamadermatol.2026.3199}
}
Kostenlos starten →